PHARMACY

Bristol-Myers Squibb completes part of Medarex acquisition

BY Alaric DeArment

NEW YORK Bristol-Myers Squibb Co. has completed the initial part of its $2.4 billion tender offer for a Princeton, N.J.-based biotech company, the New York-based drug maker announced Thursday.

Bristol said 87.7% of shares of Medarex had been offered for sale and that it would attempt to acquire the remaining 12.3%. The offer for the remaining shares will expire at midnight Monday.

Medarex develops monoclonal antibodies using its UltiMAb platform.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA allows DoD to distribute swine flu test to soldiers

BY Alaric DeArment

ROCKVILLE, Md. The Food and Drug Administration will allow the Department of Defense to distribute a test for detecting the swine flu in soldiers serving overseas.

The FDA announced Tuesday that it had issued an emergency use authorization for the test, developed by the Centers for Disease Control and Prevention and called the CDC swH1N1 Influenza Real-Time RT-PCR. An EUA allows the use of unapproved medical products or unapproved uses of them during a declared public health emergency. The 2009 H1N1 influenza virus was declared a global pandemic this summer, making it the first influenza pandemic since 1968.

“The FDA worked quickly with the Defense Department to authorize the use of this test to better protect our troops,” FDA commissioner Margaret Hamburg said in a statement. “The test will aid in more rapid diagnosis of 2009 H1N1 influenza infections so that deployed troops can quickly begin appropriate medical treatment.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Study finds leukotriene modifiers work best for asthma sufferers

BY Alaric DeArment

WILMINGTON, Del. Asthma patients have an easier time controlling their disease with oral controllers than with a common type of inhaled drug, according to a new study.

In a peer-reviewed study requested by WellPoint, conducted by HealthCore and published in Mayo Clinic Proceedings, patients taking oral controllers called leukotriene modifiers had better clinical results than those taking inhaled corticosteroids.

“Clinical superiority of the inhaled products has been well-documented in clinical trials, and the HealthCore study confirmed this for those who take their medication properly,” HealthCore VP clinical affairs Joseph Singer said in a statement. “However, we were surprised to discover that in looking at all patients in real-world settings, oral controllers appeared to be a better choice of treatment because of better compliance.”

Common leukotriene modifier brands include Merck & Co.’s Singulair (montelukast sodium), AstraZeneca’s Accolate (zafilukast) and Cornerstone Therapeutics’ Zyflo (zileuton).

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?